3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Other hematologic neoplasm
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Conditions
Urinary Bladder Neoplasms
2
Salivary Gland Neoplasms
2
Prostatic Neoplasms
2
Pancreatic Neoplasms
2
Ovarian Neoplasms
2
Lung Neoplasms
2
Hematologic Neoplasms
2
Colorectal Neoplasms
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Thyroid Neoplasms
1
Stomach Neoplasms
1
Skin Neoplasms
1
Rectal Neoplasms
1
Neoplasms
1
Multiple Myeloma
1
Melanoma
1
Lymphoma
1
Glioma
1
Gallbladder Neoplasms
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Hepatocellular
1
Breast Neoplasms
1
Interventions
pembrolizumab
8
Radiotherapy
2
Nivolumab
2
Drug Therapy
2
Biopsy
2
pertuzumab
1
liposomal doxorubicin
1
cemiplimab
1
cc-486
1
brodalumab
1
atezolizumab
1
Trastuzumab
1
Therapeutics
1
Surveys and Questionnaires
1
Semaxinib
1
SUB1 protein, human
1
Radiosurgery
1
Quality of Life
1
Patient Reported Outcome Measures
1
Paclitaxel
1
Oxaliplatin
1
Observation
1
Molecular Diagnostic Techniques
1
Magnetic Resonance Spectroscopy
1
Lighting
1
Isotretinoin
1
Interleukin-2
1
Interferon-alpha
1
Injections
1
Immunotherapy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Skin Neoplasms
×
pertuzumab
×
Head & Neck
×
Clear all
NCT05786716
2025-12-02
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
30 enrolled